Apixaban is a potent, reversible, direct inhibitor of factor Xa. 9 In a phase 2 study, 10 the dose identified as appropriate for testing in phase 3 studies with patients undergoing major joint ...

Dr. Marcus hypothesized that dosing may be a reason for apixaban’s apparently reduced risk of GI bleeding: “As a once-a-day drug, Xarelto [rivaroxaban] exhibits a pretty steep peak level in ...

Researchers sought to determine whether a reduced dose of apixaban would be as effective as using full-dose apixaban in preventing recurrent VTE in patients with active cancer.

a P for interaction = 0.37.. Rates of stroke and bleeding increased with higher CHADS 2 scores, but apixiban compared with aspirin was associated with a similar risk of bleeding (P for interaction = 0 ...

Apixaban is a direct-acting oral anticoagulant that has an excellent risk–benefit profile for stroke prevention among patients with clinical atrial fibrillation. 3,5 The Apixaban for the ...

In the patients that were switched from apixaban to rivaroxaban, that was associated with a higher risk of stroke/systemic embolism and major bleeding, with a pretty impressive hazard ratio of 1. ...

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status. Impaired kidney function is the principal predictor of hemorrhage in ...

The findings of the AVERROES trial foretell a future with appropriate treatment for patients with atrial fibrillation who are not candidates for anticoagulation with oral vitamin-K antagonists.